Stryker Corporation — Q3 2023 Form 10-Q
Business context and period: Medical technology company reporting the three and nine months ended September 30, 2023. Its reportable segments are MedSurg and Neurotechnology, and Orthopaedics and Spine. Dollar amounts are in millions except per-share data.
Financial performance
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Net sales | $4,909 (+9.6%) | $4,479 | $14,683 (+10.8%) | $13,247 |
| Gross margin | 64.3% | 62.1% | 63.7% | 63.0% |
| Operating income / margin | $931 / 19.0% | $808 / 18.0% | $2,631 / 17.9% | $2,027 / 15.3% |
| Net earnings | $692 | $816 | $2,022 | $1,795 |
| Diluted EPS | $1.80 | $2.14 | $5.27 | $4.70 |
| Adjusted diluted EPS | $2.46 (+16.0%) | $2.12 | $7.14 (+12.6%) | $6.34 |
Q3 sales increased 9.3% in constant currency; growth excluding acquisitions and divestitures reflected higher volume and modestly higher prices. Nine-month constant-currency sales growth was 11.7%. Q3 MedSurg and Neurotechnology sales grew 10.5% and Orthopaedics and Spine grew 8.4% as reported.
Q3 gross-margin expansion reflected favorable volume and lower manufacturing and supply-chain costs versus the prior-year quarter. SG&A rose 16.9%, driven mainly by investment and spending to support growth. In Orthopaedics and Spine, operating margin declined to 24.3% from 28.2%, with higher SG&A and manufacturing costs cited; MedSurg and Neurotechnology margin rose to 30.0% from 23.6%.
Reported Q3 net earnings and EPS declined despite higher sales and operating income. The company cited higher interest expense and the prior-year release of $50 of accrued interest tied to a federal tax audit settlement; the Q3 effective tax rate was 20.4%, versus 0.0% in 2022. Adjusted results exclude specified items and are non-GAAP measures.
Cash, debt and liquidity
- Nine-month operating cash flow was $2,183, up from $1,621; investing cash outflow was $810 and financing cash outflow was $1,308. Inventories used $922 of operating cash.
- Cash and cash equivalents were $1,860 at September 30, 2023; cash, cash equivalents and marketable securities totaled $1,936. Working capital was $3,587.
- Total debt was $12,690, including $2,308 classified as current maturities. The company repaid the remaining $650 term-loan balance in August and issued €500 of floating-rate notes due November 2024. No commercial paper or revolving-credit borrowings were outstanding; it reported compliance with debt covenants.
- Capital expenditures were $430 for the nine months. Dividends paid were $854; no shares were repurchased.
Outlook, risks and notable items
- The filing provides no specific numerical forward guidance in the supplied text. Management expects macroeconomic pressures—including inflation, labor and shipping costs, higher interest rates, currency fluctuations, and geopolitical conflicts—to continue; these could affect customer orders and capital-product mix.
- China’s volume-based procurement programs have pressured prices for certain joint replacement, trauma and neurovascular products. Stryker is exiting its China spine business after an unsuccessful bid. China represented approximately 1.9% of nine-month revenue. Import-purchase policies and an anti-corruption campaign also pose uncertainties.
- The company is investigating potential Foreign Corrupt Practices Act issues in certain foreign countries, is cooperating with the SEC, DOJ and other authorities, and says it cannot predict the outcome or financial impact.
- Recall reserves were $198. Stryker cautions that ultimate costs could differ materially. A separate PureWick patent case involving PrimaFit products had a trial scheduled for December 2023; the company also plans to appeal an earlier judgment.
- Cerus was acquired in May for $289 cash, with up to $225 in milestone payments. Its purchase-price allocation remained preliminary.
Important facts for investors to verify
- Whether sales growth and margin trends persist, particularly in Orthopaedics and Spine amid higher costs and pricing pressure.
- How much reported-versus-adjusted earnings differences reflect recurring costs, and whether adjusted measures remain comparable over time.
- Inventory levels and working-capital conversion, given the $922 nine-month inventory cash outflow.
- Debt maturities, refinancing needs, and interest costs, including the floating-rate 2024 notes.
- Developments and potential financial exposure from the FCPA investigation, product recalls and PureWick litigation.
- Effects of China procurement and policy changes on pricing, sales volume and market access.